Cargando…
Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients
The UK audit was undertaken in primary breast cancer patients receiving adjuvant chemotherapy to: (1) record the incidence of neutropenic events (hospitalisation due to febrile neutropenia, dose delay of ⩾1 week or dose reduction of ⩾15% due to neutropenia); (2) evaluate the impact of neutropenic ev...
Autores principales: | Leonard, R C F, Miles, D, Thomas, R, Nussey, F |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376842/ https://www.ncbi.nlm.nih.gov/pubmed/14647139 http://dx.doi.org/10.1038/sj.bjc.6601279 |
Ejemplares similares
-
Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer
por: Cameron, D A, et al.
Publicado: (2003) -
Adjuvant Chemotherapy for Breast Cancer in a Patient with Primary Autoimmune Neutropenia
por: Trus, Michael, et al.
Publicado: (2013) -
Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy
por: Hashiguchi, Yasunori, et al.
Publicado: (2015) -
Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy
por: Ray-Coquard, I, et al.
Publicado: (2003) -
Block sequential adriamycin CMF – optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?
por: Cameron, D A, et al.
Publicado: (2002)